Statistical validation of the criteria for symptom remission in schizophrenia: Preliminary findings

BMC Psychiatry

Volumn 7, Issue , 2007, Pages

  Opler, Mark G A ^a,c   Yang, Lawrence H ^a,c   Caleo, Sue ^b   Alberti, Philip ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c PANSS Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL EVALUATION; EMPLOYMENT; FEMALE; HUMAN; INDEPENDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PROGNOSIS; PSYCHOMETRY; RATING SCALE; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; VALIDATION PROCESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALIDATION STUDY;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; EMPLOYMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34548176109     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-7-35     Document Type: Article

References (20)

1. Corrigan PW Recovery from schizophrenia and the role of evidence-based psychosocial interventions Expert Rev Neurother 2006, 6(7): 993-1004 10.1586/14737175.6.7.993 16831114
2. Sethuraman G Taylor CC Enerson M Dunayevich E A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia Schizophr Res 79(2-3):337-40 2005 Nov 15 16054802
3. Kissling W Heres S Lloyd K Sacchetti E Bouhours P Medori R Llorca PM Direct transition to long-acting risperidone - analysis of long-term efficacy J Psychopharmacol 2005 19(5 Suppl):15-21 10.1177/ 0269881105056514 16144782
4. van Os J Drukker M A Campo J Validation of remission criteria for schizophrenia Am J Psychiatry 2006, 163:2000-02 10.1176/ appi.ajp.163.11.2000 17074953
5. Docherty JP Bossie CA Lachaux B Bouhours P Zhu Y Lasser R Gharabawi GM Patient-based and clinician-based support for the remission criteria in schizophrenia Int Clin Psychopharmacol 2007, 22(1):51-5 17159460
6. Weiden P Zygmunt A Medication noncompliance in schizophrenia. Part I. Assessment J PracPsychiatry Behav Health 1997, 3:106-110
7. White L Harvey PD Opler L Lindenmayer JP Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale The PANSS Study Group. Psychopathology 1997, 30(5):263-274
8. van den Oord EJ Rujescu D Robles JR Giegling I Birrell C Bukszar J Murrelle L Moller HJ Middleton L Muglia P Factor structure and external validity of the PANSS revisited Schizophr Res 2005,Oct 14 16229988
9. Lasser RA Bossie CA Gharabawi GM Kane JM Remission inschizophrenia: Results from a 1-year study of long-acting risperidoneinjection Schizophr Res 77(2-3):215-27 2005 Sep 15 15908183
10. Leucht S Kane JM Kissling W Hamann J Etschel E Engel RR What does the PANSS mean? Schizophr Res 79(2-3):231-8 2005 Nov 15 15982856
11. Mahmoud R Engelhart L Ollendorf D Oster G The Risperidone Outcomes Study of Effectiveness (ROSE):A Model for Evaluating Treatment Strategies in Typical Psychiatric Practice J Clin Psychiatry 1999, 60(suppl 3):42-47 10073377
12. Hatta K Nakamura H Matsuzaki I Acute-phase treatment in general hospitals: Clinical psychopharmacologic evaluation in first-episode schizophrenia patients Gen Hosp Psychiatry 2003, 25(1):39-45 10.1016/ S0163-8343(02)00252-9 12583927
13. Kozuki Y Schepp KG Adherence and nonadherence to antipsychotic medications Issues Ment Health Nurs 2005, 26(4)):379-96 10.1080/ 01612840590922425 16020055
14. Hudson TJ Owen RR Thrush CR Han X Pyne JM Thapa P Sullivan G A pilot study of barriers to medication adherence in schizophrenia J Clin Psychiatry 2004, 65(2):211-6 15003075
15. Opler L Malaspina D Opler M Reducing guesswork in schizophrenia treatment Current Psychiatry 2006, 5(9):76-84
16. Rabinowitz J Bromet EJ Davidson M Are patients enrolled in first episode psychosis drug trials representative of patientstreated in routine clinical practice? Schizophr Res 61 (2-3):149-55 2003 Jun 1 12729866
17. Phillips GA Van Brunt DL Roychowdhury SM Xu W Naber D The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone J Clin Psychiatry 2006, 67(9):397-403 17017826
18. The PANSS Manual Kay, Opler, and Fiszbein: © Multi-Health Systems, Inc., Toronto, CA; 2006.
19. Gorwood P Meeting everyday challenges: Antipsychotic therapy in the real world Eur Neuropsychopharmacol 2006, 16(Suppl 3):S156-62 Epub 2006 Jul 25 10.1016/j.euroneuro.2006.06.002 16872807
20. Lysaker PH Buck KD Hammoud K Taylor AC Roe D Associations of symptoms, psychosocial function and hope with qualities of self-experience in schizophrenia: Comparisons of objective and subjective indicators of health Schizophr Res 2006, 82:2-3 10.1016/j.schres.2005.12.844